PDCT-24. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS-RAF PATHWAY-ACTIVATED TUMORS: INITIAL REPORT

BACKGROUND: Ras/Raf/MEK/ERK pathway activation is the primary driver of most pediatric low-grade gliomas (LGG), the most common brain tumor in children. Unresectable LGG are associated with multiple recurrences and significant long-term morbidity. MEK162 is an orally bioavailable inhibitor of MEK1/2...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Robison, Nathan, Pauly, Jasmine, Malvar, Jemily, Filbin, Mariella, de Mola, Rebecca Loret, Dorris, Kathleen, Bendel, Anne, Bowers, Daniel, Bornhorst, Miriam, Gauvain, Karen, Leary, Sarah, MacDonald, Tobey, Gardner, Sharon, Reddy, Alyssa, Diaz, Patricia, Tan, Yi Juin, Sinai, Claire, Davidson, Tom, Ullrich, Nicole, Margol, Ashley, Dhall, Girish, Borchert, Mark, Ligon, Keith, Sposto, Richard, Kieran, Mark
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2017
Aiheet:
Abstracts
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5692641/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.765
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia